Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
An attempt to abrogate the placebo response does not seem to have gone as planned.
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
November 6 is the day that could make or break Biogen.
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
As antibody tests pile up, Oxford Immunotec is working on an assay to detect T-cell responses to the coronavirus.
Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.
The German group has come late to antibody testing, but has punchy accuracy data and a possible means of neutralising some of the competition.